The ITN, led by Hannover Medical School (MHH), pursues an inter-sectoral approach to develop novel strategies for treating spinal muscular atrophy (SMA), a rare neurodegenerative disease with a significant unmet medical need.
Ascenion will provide training to raise the researchers’ awareness for the commercial and societal impact of their work. The technology managers and legal experts will also be available to consult the consortium on IP-relevant questions or issues that may arise throughout their collaboration.
The SMABEYOND network is funded by the European Union for four years with a total of EUR 2.14 million under the Horizon 2020 program.